| wang, shusen |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
NCT05430399: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 349 | RoW | utidelone, docetaxel | Sun Yat-sen University, Beijing Biostar Pharmaceuticals Co., Ltd., Hunan Cancer Hospital | Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | 06/25 | 06/27 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 06/25 | 12/26 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 05/25 | 05/25 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC |
|
|
| Terminated | 2 | 9 | RoW | Chiauranib, capecitabine | Chipscreen Biosciences, Ltd. | Triple-negative Breast Cancer | 10/24 | 11/24 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
| Recruiting | 1 | 40 | RoW | TQB3728 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/21 | 05/22 | | |
| Recruiting | 1 | 70 | RoW | TQB3915 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06381050: The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SHR-7631 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 04/26 | 04/27 | | |
NCT05414136: Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 |
|
|
| Completed | 1 | 37 | RoW | BAT1006, Recombinant humanized anti-HER2 monoclonal antibody for injection | Bio-Thera Solutions | Advanced Solid Tumor | 06/24 | 06/24 | | |
| Active, not recruiting | 1 | 164 | RoW | TQB3823 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 02/25 | 10/25 | | |
NCT05848466: Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients |
|
|
| Recruiting | 1 | 109 | RoW | BAT8010 for Injection | Bio-Thera Solutions | Advanced or Metastatic Solid Tumors | 05/25 | 07/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
